

Annalisa Chiappella

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3821025/annalisa-chiappella-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

170
papers

2,882
citations

32
h-index

50
g-index

184
ext. papers

3,431
ext. citations

4
avg, IF

4.44
L-index

#	Paper	IF	Citations
170	Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study. <i>Blood</i> , 2021 , 138, 134-134	2.2	1
169	Tisagenlecleucel and Axicabtagene Ciloleucel Expansion Kinetics and CAR T Cell Attributes in the Infusion Products Are Early Predictors of Clinical Efficacy. <i>Blood</i> , 2021 , 138, 3877-3877	2.2	
168	Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem. <i>Blood</i> , 2021 , 138, 3867-3867	2.2	0
167	CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). <i>Haematologica</i> , 2021 , 106, 2918-2926	6.6	3
166	Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2021 , 1-10	1.9	1
165	A three-gene signature based on , and improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021 , 106, 2405-2416	6.6	4
164	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1317-1328	2.2	32
163	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021 , 35, 787-795	10.7	19
162	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021 , 8, e34-e44	14.6	9
161	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2606-2609	4.4	1
160	The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma. <i>Lancet Haematology</i> , 2021 , 8, e617-e619	14.6	
159	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. <i>Blood Advances</i> , 2021 , 5, 640-648	7.8	6
158	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , 2021 , 13,	6.6	5
157	A Novel Method for Molecular Enumeration of Circulating Tisa-Cel and Axi-Cel in Lymphoma Patients. <i>Blood</i> , 2020 , 136, 48-49	2.2	
156	Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 41-42	2.2	2
155	Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting. <i>Blood</i> , 2020 , 136, 12-13	2.2	1
154	Selective inhibitors of nuclear export in aggressive B-cell lymphomas. <i>Lancet Haematology</i> , 2020 , 7, e500-e501	14.6	1

153	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. <i>Lancet Haematology, the</i> , 2020 , 7, e649-e659	14.6	12
152	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020 , 105, e72-e75	6.6	5
151	High-grade B-cell lymphoma: how to diagnose and treat. <i>Expert Review of Hematology</i> , 2019 , 12, 497-506	6.8	5
150	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 628-634	7.1	7
149	Monoclonal antibody-drug conjugates in B-cell lymphomas. <i>Lancet Haematology, the</i> , 2019 , 6, e232-e233	14.6	1
148	Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2019 , 185, 330-334	4.5	4
147	Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence. <i>Expert Review of Hematology</i> , 2019 , 12, 787-796	2.8	4
146	OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY. <i>Hematological Oncology</i> , 2019 , 37, 46-47	1.3	2
145	Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi. <i>Blood</i> , 2019 , 134, 398-398	2.2	5
144	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019 , 134, 4092-4092	2.2	1
143	Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQL) Analysis of the International Robust Study. <i>Blood</i> , 2019 , 134, 3475-3475	2.2	
142	The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12. <i>Fondazione Italiana Linfomi Blood</i> , 2019 , 134, 3025-3025	2.2	
141	Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019 , 24, 1246-1252	5.7	7
140	IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019 , 37, 244-245	1.3	1
139	P14.85 Brain metastasis from Hodgkin Lymphoma: case report and literature review. <i>Neuro-Oncology</i> , 2019 , 21, iii87-iii88	1	78
138	Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?. <i>HemaSphere</i> , 2019 , 3, e284	0.3	7
137	Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. <i>British Journal of Haematology</i> , 2019 , 185, 940-944	4.5	30
136	Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience. <i>Annals of Hematology</i> , 2018 , 97, 1619-1626	3	3

135	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2904-2910	1.9	5
134	Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era. <i>Lancet Oncology, The</i> , 2018 , 19, 162-163	21.7	4
133	Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study. <i>British Journal of Haematology</i> , 2018 , 182, 453-456	4.5	3
132	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the. <i>Haematologica</i> , 2018 , 103, 1345-1350	6.6	26
131	Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma. <i>Lancet Oncology, The</i> , 2018 , 19, 1144-1146	21.7	1
130	Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 449-449	2.2	4
129	Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2018 , 132, 401-401	2.2	6
128	Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies. <i>Blood</i> , 2018 , 132, 676-676	2.2	1
127	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018 , 132, 2962-2962	2.2	1
126	Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi. <i>Blood</i> , 2018 , 132, 2902-2902	2.2	2
125	Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7548-7548	2.2	1
124	Long term follow-up (FU) of lenalidomide plus R-CHOP therapy in patients with newly diagnosed diffuse large b-cell lymphoma (DLBCL): Combined analysis from two phase 2 trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7562-7562	2.2	1
123	Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified. <i>Blood</i> , 2018 , 132, 4115-4115	2.2	
122	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. <i>Blood Cancer Journal</i> , 2018 , 8, 108	7	22
121	Histological transformation and secondary malignancies in follicular lymphoma. <i>Lancet Haematology,the</i> , 2018 , 5, e496-e497	14.6	1
120	A Prospective, Observational Study Evaluating Early Subclinical Cardiotoxicity with Global Longitudinal Strain Imaging in Lymphoma Patients Treated with Chemotherapy +/- Mediastinal Radiation Therapy: The CARDIOCARE Project. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, S88	4	2
119	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. <i>Annals of Oncology</i> , 2018 , 29, 2363-2370	10.3	47
118	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018 , 8, 63	7	9

117	Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. <i>Blood</i> , 2017 , 129, 2328-2330	2.2	59
116	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology, the</i> , 2017 , 4, e15-e23	14.6	75
115	Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives. <i>Expert Review of Hematology</i> , 2017 , 10, 289-297	2.8	21
114	Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply. <i>Lancet Oncology, The</i> , 2017 , 18, e558	21.7	0
113	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2017 , 18, 1076-1088	21.7	72
112	Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2017 , 10, 697-705	2.8	24
111	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 42-49	4	21
110	CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. <i>American Journal of Hematology</i> , 2017 , 92, E1-E2	7.1	22
109	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). <i>Thrombosis and Haemostasis</i> , 2017 , 117,	7	19
108	State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016 , 30, 1147-1162	3.1	9
107	PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). <i>Thrombosis Research</i> , 2016 , 140 Suppl 1, S177	8.2	16
106	Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 1239-43	4	18
105	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1823-30	1.9	23
104	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. <i>Blood</i> , 2016 , 128, 3033-3033	2.2	2
103	Peripheral T-Cell Lymphomas Not Otherwise Specified: Potential Novel Molecular Entities Based on Both Tumor and Microenvironment Cellular Components. <i>Blood</i> , 2016 , 128, 4098-4098	2.2	2
102	A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 4199-4199	2.2	1
101	Post Relapse Survival Rates in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 4204-4204	2.2	5
100	Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi. <i>Blood</i> , 2016 , 128, 472-472	2.2	2

99	Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study. <i>Blood</i> , 2016 , 128, 622-622	2.2	20
98	Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7538-7538	2.2	2
97	Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohistochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP. <i>Blood</i> , 2016 , 128, 5305-5305	2.2	
96	The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 3049-3049	2.2	1
95	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016 , 12, 1553-63	3.6	66
94	Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab. <i>Journal of Chemotherapy</i> , 2016 , 28, 435-40	2.3	2
93	A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 38	22.4	26
92	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016 , 101, e196-9	6.6	13
91	A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2015 , 26, 1667-77	10.3	67
90	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. <i>Leukemia</i> , 2015 , 29, 1390-401	10.7	32
89	Changing treatment paradigms in lymphoma: new targets and new drugs. <i>Memo - Magazine of European Medical Oncology</i> , 2015 , 8, 184-188	0.3	
88	Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2015 , 6, 6921	17.4	81
87	The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015 , 126, 2735-2735	2.2	2
86	GATA-3 Expression in Peripheral T-Cell Lymphomas (PTCL): Identification of a Cut-Off and Prognostic Value in PTCL-NOS Versus Others Hystotypes. <i>Blood</i> , 2015 , 126, 3889-3889	2.2	1
85	Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. <i>Blood</i> , 2015 , 126, 3937-3937 ^{2.2}		
84	The Prognostic Role of Cell of Origin Profile and Myc Expression Assessed By Immunohistochemistry in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of First-Line Randomized BIO-DLCL04 Trial of Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015 , 126, 3044-3044	2.2	
83	Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015 , 126, 3934-3934	2.2	
82	De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC). <i>Blood</i> , 2015 , 126, 2650-2650	2.2	

81	A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2014 , 25, 2398-2404	10.3	10
80	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014 , 25, 1404-1410	10.3	114
79	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 730-7	21.7	135
78	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2014 , 99, 489-96	6.6	46
77	Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. <i>Blood Cancer Journal</i> , 2014 , 4, e249	7	9
76	Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2014 , 124, 1755-1755	2.2	2
75	The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP. <i>Blood</i> , 2014 , 124, 2964-2964	2.2	2
74	Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2014 , 124, 3074-3074	2.2	1
73	Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 87, 311-6	4	33
72	The risk of CNS involvement in aggressive lymphomas in the rituximab era. <i>Expert Review of Hematology</i> , 2013 , 6, 643-52	2.8	1
71	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , 2013 , 54, 699-707	1.9	32
70	Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013 , 24, 2251-2	2.2	48
69	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013 , 54, 53-7	1.9	36
68	Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. <i>Annals of Oncology</i> , 2013 , 24, 2119-23	10.3	78
67	XVI. CNS prophylaxis in aggressive lymphomas: for whom and how. <i>Hematological Oncology</i> , 2013 , 31 Suppl 1, 89-91	1.3	1
66	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013 , 122, 3759-66	2.2	63
65	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2013 , 98, 1732-8	6.6	48
64	Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi. <i>Blood</i> , 2013 , 122, 3047-3047	2.2	2

63	Comparison Of R-CHOP14 and R-CHOEP14 As First Line Treatment In Young Patients With High-Risk (aaIPI 2-3) Diffuse Large B-Cell Lymphoma (DLBCL): A Joint Analysis Of Two Prospective Phase III Randomized Trials Conducted By The Fondazione Italiana Linfomi (FIL) and The German High-Grade Lymphoma Study Group (DSHNHL). <i>Blood</i> , 2013 , 122, 4341-4341	2.2	3
62	Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi. <i>Blood</i> , 2013 , 122, 850-850	2.2	3
61	Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi. <i>Blood</i> , 2013 , 122, 5088-5088	2.2	
60	Impact Of Bone Marrow Involvement On Outcome Of Young Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Treated In The Phase III Randomized Trial (DLCL04) With Rituximab Dose-Dense Chemotherapy Followed By Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Or Standard Rituximab Dose-Dense Chemotherapy: A Study	2.2	
59	Relapsed Or Refractory Aggressive Non Hodgkin B-Cell Lymphomas Treated With Lenalidomide With/Without Rituximab Or Steroids: A Single Center Restrospective Study. <i>Blood</i> , 2013 , 122, 5119-5119 ^{2.2}		
58	Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. <i>Blood</i> , 2012 , 119, 2066-73	2.2	186
57	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012 , 53, 581-8	1.9	56
56	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , 2012 , 23, 729-735	10.3	17
55	ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. <i>Frontiers in Oncology</i> , 2012 , 2, 41	5.3	33
54	Lenalidomide in diffuse large B-cell lymphomas. <i>Advances in Hematology</i> , 2012 , 2012, 498342	1.5	10
53	Rituximab Dose-Dense Chemotherapy Followed by Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Significantly Reduces the Risk of Progression Compared to Standard Rituximab Dose-Dense Chemotherapy As First Line Treatment in Young	2.2	14
52	Patients with High Risk (aa-IPI ≥2) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results of Phase II Randomized Trial of Lenalidomide Plus Rituximab-CHOP21 (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012 , 120, 903-903	2.2	2
51	R-CHOP21 Vs R-CHOP14 in 950 Diffuse Large B-Cell Lymphoma Patients: Results of a Multicentre Retrospective Study Form Italian Lymphoma Foundation (FIL). <i>Blood</i> , 2012 , 120, 1615-1615	2.2	
50	Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 149-51	2	5
49	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2011 , 117, 2405-13	2.2	28
48	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , 2011 , 153, 499-503	4.5	11
47	Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , 2011 , 155, 274-7	4.5	42
46	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , 2011 , 29, 38-41	1.3	23

45	First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2766-72	2.2	135
44	Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian	2.2	4
43	Radioimmunotherapy (RIT) with 90yttrium Zevalin Followed by BEAM Conditioning Regimen (Z-BEAM) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of High Risk Relapsed/Resistant Non Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2011 , 118, 3107-3107	2.2	
42	Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2B) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis. <i>Blood</i> , 2011 , 118, 1606-1606	2.2	
41	Rituximab Plus Dose Intense Rapid-Cycling Chemotherapy with Intrathecal CNS Prophylaxis in Patients with Burkitt Lymphoma (BL) and Intermediate Unclassifiable Diffuse Large B-Cell Lymphoma/BL: Single Institution Experience. <i>Blood</i> , 2011 , 118, 1631-1631	2.2	
40	Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. <i>British Journal of Haematology</i> , 2010 , 151, 221-31	4.5	45
39	Nonpegylated liposomal doxorubicin (Myocet TM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. <i>Annals of Oncology</i> , 2010 , 21, 1492-1499	10.3	72
38	Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 115-22	4.7	51
37	Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 611-5	4.9	25
36	Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)-rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. <i>Cancer</i> , 2010 , 116, 4573-9	6.4	24
35	The Outcome of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP (R-CHOP) Is Not Predicted by 18-FDG-Positron Emission Tomography/Computerized Tomography (PET) Performed at Intermediate In-Course Evaluation, but Only by PET Assessed at the End of Therapy. <i>Blood</i> , 2010 , 116, 2819-2819	2.2	3
34	Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin's Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients.. <i>Blood</i> , 2010 , 116, 2821-2821	2.2	1
33	Weekly Infusion of Bortezomib In Combination with Rituximab In Relapsed/Refractory Indolent Non-Follicular and Mantle Cell Lymphoma Is Safe and Effective: Two-Years Analysis of Phase II Trial BRIL06 of Intergruppo Italiano Linfomi (IIL). <i>Blood</i> , 2010 , 116, 3965-3965	2.2	1
32	Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy. <i>Blood</i> , 2010 , 116, 1784-1784	2.2	1
31	Outcome of Elderly Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Prospectively Identified by Comprehensive Geriatric Assessment (CGA). Results From a Study of the Intergruppo Italiano Linfomi (IIL). <i>Blood</i> , 2010 , 116, 1771-1771	2.2	0
30	The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study. <i>Blood</i> , 2010 , 116, 992-992	2.2	
29	Prospective, Multicenter Phase III Pilot Trial to Evaluate Efficacy and Safety of Lenalidomide Plus Rituximab-CHOP21 (LR-CHOP21) for Elderly Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis of the Intergruppo Italiano Linfomi (IIL) REAL07 Study. <i>Blood</i> , 2010 , 116, 2871-2871	2.2	
28	Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. <i>Leukemia</i> , 2009 , 23, 1118-26	10.7	87

27	Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 381-5		61
26	Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , 2009 , 94, 1250-8	6.6	56
25	Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.. <i>Blood</i> , 2009 , 114, 1706-1706	2.2	1
24	The Combination of Bortezomib and Rituximab Is Effective and Safe in Relapsed/Refractory Indolent Non Follicular and Mantle-Cell Non Hodgkin Lymphoma: a Phase II Multicenter Study by Intergruppo Italiano Linfomi.. <i>Blood</i> , 2009 , 114, 3758-3758	2.2	2
23	Response Assessment After Induction Therapy in Diffuse Large B Cell Lymphoma (DLBCL): Role of Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) in Comparison with Computed Tomography (CT).. <i>Blood</i> , 2009 , 114, 4995-4995	2.2	1
22	Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP.. <i>Blood</i> , 2009 , 114, 99-99	2.2	7
21	Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.. <i>Blood</i> , 2009 , 114, 2928-2928	2.2	
20	Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP.. <i>Blood</i> , 2009 , 114, 3957-3957	2.2	
19	Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).. <i>Blood</i> , 2009 , 114, 2316-2316	2.2	
18	The Host Genetic Background of DNA Repair Mechanisms Represents An Independent Predictor of Progression and Survival in Diffuse Large B-Cell Lymphoma Treated with R-CHOP.. <i>Blood</i> , 2009 , 114, 442-442	2.2	
17	Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. <i>Radiologia Medica</i> , 2008 , 113, 578-90	6.5	78
16	Brief Chemoimmunotherapy Rituximab (R)-FND + R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial. <i>Blood</i> , 2008 , 112, 834-834	2.2	1
15	The Pharmacogenetic Background of the Host Is An Independent Predictor of Outcome and Toxicity in Diffuse Large B Cell Lymphoma Treated with R-CHOP21. <i>Blood</i> , 2008 , 112, 480-480	2.2	
14	Radioimmunotherapy (RIT) with 90y-Ibritumomab Tiuxetan (Zevalin) in Relapsed or Refractory Aggressive Lymphoma Previously Treated with Rituximab Containing Regimens. <i>Blood</i> , 2008 , 112, 5014-5014	2.2	
13	Activated B-Cell (ABC) Profile Does Not Have An Inferior Outcome Compared to Germinal Center B-Cell (GCB) Profile Determined by Immunohistochemistry Tissue Microarray in Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and Dose- Dense and High-Dose Chemotherapy (HDC) Plus Autologous Stem Cell Transplantation (ASCT).. <i>Blood</i> , 2008 , 112, 1139-1139	2.2	
12	Validation of Mantle Cell International Prognostic Index (MIPI) in Mantle Cell Lymphoma (MCL) in a Retrospective Single Institution Series. <i>Blood</i> , 2008 , 112, 2828-2828	2.2	
11	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2008 , 112, 478-478	2.2	
10	Quantification by Superconducting Quantum Interference Device (SQUID) of Iron Overload after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).. <i>Blood</i> , 2008 , 112, 2134-2134	2.2	

9	Mid-Treatment 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Does Not Impact the Outcome in Patients with Aggressive Non Hodgkin Lymphoma (NHL). <i>Blood</i> , 2008 , 112, 5295-5295	2.2	1
8	Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation + Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638). <i>Blood</i> , 2007 , 110, 1278-1278	2.2	1
7	Mid-Treatment Evaluation of 18-FDG-Positron Emission Tomography/Computed Tomography (PET) as Predictive Value of Response Assessment in Aggressive Non Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007 , 110, 2333-2333	2.2	1
6	Radioimmunotherapy (RIT) with 90Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience.. <i>Blood</i> , 2007 , 110, 4478-4478	2.2	3
5	Rituximab (R) in Addition to Dose-Dense Chemotherapy MegaCEOP and Intensification with R-MAD Followed by High Dose Chemotherapy BEAM with Autologous Stem Cell Transplantation (ASCT) Is Safe and Effective in Untreated High Risk Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007 , 110, 1899-1899	2.2	1
4	Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.. <i>Blood</i> , 2006 , 108, 208-208	2.2	4
3	Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage III/IV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial.. <i>Blood</i> , 2006 , 108, 329-329	2.2	2
2	Pre-Autologous Stem Cell Transplantation (ASCT) Treatment with Rituximab Does Not Impair Stem Cell Harvest and Engraftment in Untreated Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.. <i>Blood</i> , 2005 , 106, 2738-2738	2.2	1
1	Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.. <i>Blood</i> , 2005 , 106, 676-676	2.2	